 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
8 News |  |
| 12345678910» |
- | Vemlidy (tenofovir alafenamide) / Gilead
Journal: High plasma concentration of tenofovir alafenamide in people living with HIV with ABCB1 genetic variants. (Pubmed Central) - Jan 18, 2025
The allelic variant ABCB1 4036 A
- | bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel. (Pubmed Central) - Dec 1, 2024
Disparities in HIV acquisition and care access are discussed and solutions proposed. New approaches for treating and preventing HIV offer additional tools to help end the HIV epidemic, but achieving this goal depends on addressing disparities and inequities in access to care.
- || bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Review, Journal: Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives. (Pubmed Central) - Nov 27, 2024
In this manuscript, we review weight changes among PLWH receiving HAART and the relevant underlying pathogenic mechanisms described in recent literature. We try to provide a more critical appraisal of the available data and to underline the challenges in assessing the role of HAART in weight changes in both ART initiation and setting switching.
- || Sunlenca (lenacapavir) / Gilead, bictegravir (GS-9883) / Gilead
P2 data, Journal: Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). (Pubmed Central) - Nov 26, 2024
P2/3
We try to provide a more critical appraisal of the available data and to underline the challenges in assessing the role of HAART in weight changes in both ART initiation and setting switching. These data support the continued evaluation of the combination of BIC and LEN to optimize treatment in people with HIV and virologic suppression who are receiving complex ART regimens.
- | Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Vemlidy (tenofovir alafenamide) / Gilead
Journal, Adherence: Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF). (Pubmed Central) - Nov 21, 2024
P
TFV-DP ?1800?fmol/punches and FTC-TP ?2.5?pmol/punches represent DBS benchmarks for ?85% adherence to unboosted TAF/FTC-based ART. Among PWH with high adherence, low-level viremia was common.
- | bictegravir (GS-9883) / Gilead, Vemlidy (tenofovir alafenamide) / Gilead, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Preclinical, Journal: A dual-purpose humanized mouse model for testing antiviral strategies against both SIV and HIV. (Pubmed Central) - Nov 19, 2024
Infected mice showing chronic viremia were treated with a combination anti-retroviral treatment (cART) regimen consisting of emtricitabine/elvitegravir/tenofovir disoproxil fumarate (FTC/EVG/TDF)...Next, a cART regimen consisting of emtricitabine/bictegravir/tenofovir alafenamide fumarate (FTC/BIC/TAF) was similarly evaluated...These findings highlight the utility of humanized mice for in vivo screening of new combinations of ARV compounds against various SIVs prior to employing them in NHPs. In addition to identifying new effective cART regimens against SIVs, this model would also be amenable to evaluating immunotherapeutic strategies using broadly neutralizing antibodies, LRAs and novel therapeutics in comparative cure studies of SIV and HIV.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Low prevalence of archived integrase strand transfer inhibitors resistance associated mutations in Botswana before the roll out of dolutegravir based first line antiretroviral therapy. (Pubmed Central) - Nov 15, 2024
Notably, bictegravir (BIC) and dolutegravir (DTG) showed no high-level resistance. The overall prevalence of archived INSTI RAMs in Botswana was low prior to transitioning to first-line DTG-based ART regimens, and did not differ between ART-na
- | Preclinical, Journal: Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction. (Pubmed Central) - Nov 13, 2024
This study evaluated the impact of lamivudine, dolutegravir (DTG), bictegravir (BIC), tenofovir disoproxil fumarate, and TAF on metabolic alterations, and explored glucose homeostasis and mitochondrial stress as potential mechanisms...BIC promoted mitochondrial dysfunction, modified carbohydrate metabolism and glucose consumption in hepatocytes, and altered glucose tolerance and gluconeogenesis regulation in mice. These findings suggest that BIC contributes to insulin resistance and diabetes in people living with HIV, warranting clinical studies to clarify its association with carbohydrate metabolism disorders.
- | bictegravir (GS-9883) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal: Immune Reconstitution Inflammatory Syndrome in a Patient With Cutaneous Leishmaniasis and HIV: A Diagnostic Challenge for Clinicians Caring for a Migrant Population in the United States. (Pubmed Central) - Oct 30, 2024
A thorough migration history was critical to diagnosis. This case highlights the different presentations of leishmaniasis in people with HIV and the elevated risk for treatment failure.
- bictegravir (GS-9883) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Immune and metabolic profile in people living with HIV initiating emtricitabine/tenofovir alafenamide/bictegravir () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_456;
FTC/TAF/BIC initiation is associated with weight gain and amelioration of immune profile both in N and E PWH. A significant reduction in LDL-c was observed only in E with COBI in previous regimen.
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Economic estimation of the management of neuropsychiatric events in people with HIV in real life (Virtual) - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_413;
Real-world discontinuation rates due to NPAEs with BIC are lower than with DTG, leading to savings in cost and resource use for their management. Findings from this study could help treatment decision-making in PHIV.
- bictegravir (GS-9883) / Gilead
Association of adenosine triphosphate?binding cassette transporter G2 (ABCG2) genetic polymorphisms with subjective symptoms and weight gain by bictegravir administration in Japanese HIV?1?infected patients () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_371;
Findings from this study could help treatment decision-making in PHIV. ABCG2 genetic polymorphism may be a predictor of subjective symptoms and weight gain with BIC administration.
- Women living with HIV: how far to fulfil the gap? () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_307;
Moreover, they were characterized by higher burden of comorbidities, in particular obesity and diabetes. That led to multiple vicious circles, enhanced by different cultural, social and economic determinants: treatment choice of 3DR versus dual regimen, difficulties in screening and management of comorbidities, lower rate of cancer screening.
- bictegravir (GS-9883) / Gilead, Pifeltro (doravirine) / Merck (MSD), Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Safety and efficacy of doravirine plus tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in heavily pre?treated patients () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_277;
Prior ARV was INSTI based in 12 cases (52%), PI based in one (4%), and both INSTI and PI in 10 (43%), with additional maraviroc in three cases (13%)...Among the four subjects with persistent low-grade viraemia, two changed to long-acting cabotegravir/rilpivirine with virological success, and two maintained the combination with last available HIV RNA of 1.82 and 1.90 logs, respectively. The use of DOR plus TAF/FTC/BIC in heavily pre-treated patients was safe
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir's effect on persistent low level viraemia and immunological response. BELAIR study: a pilot prospective observational study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_270;
The results of the present study indicate that BIC/TAF/FTC could improve the immunological response of PWH and limit the dimensions of persistent LLV reducing the risk of VF and drug-resistance issues. Further studies in larger patient series are needed in order to determine this beneficial role of BIC.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Real?life use of bictegravir/TAF/emtricitabine in a cohort of people with HIV with a high burden of comorbidities and a history of advanced HIV disease () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_269;
Additionally, significant reductions in total cholesterol and LDL indicate potential cardiovascular benefits. These findings support B/F/TAF as an effective and safe switch strategy for PWH in clinical practice, including those with advanced HIV disease and a high comorbidity burden, including psychiatric disorders.
- Evidence of resistance to integrase strand transfer inhibitors (INSTIs) among antiretroviral therapy?na () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_256;
We present the most recent data on drug resistance to integrase-based first-line regimens of HIV-1 in Greece. Our study provides evidence that major or accessory resistance mutations are detectable among ART-na
- Tivicay (dolutegravir) / ViiV Healthcare
Real?world persistence of bictegravir? versus dolutegravir?based single tablet regimens in a large urban Canadian HIV centre () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_229;
STRs containing INSTIs proved to have robust persistence with discontinuations less than 30% with a long median time to discontinuation of 402 days. BIC/FTC/TAF had a preferable portfolio of persistence over DTG-containing STR regimens overall and ABC/3TC/DTG, making it a continued important choice as an ART in first-line therapy and for switch.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Central nervous system safety of long?acting cabotegravir/rilpivirine in patients with previous oral INSTI?related CNS toxicity () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_203;
Prior to C/R, 45% (N = 13) were on NNRTI-based therapies: TAF/FTC/RPV in 11 and TAF/FTC plus doravirine in two... In this cohort of heavily pretreated patients, the rate of CNS-related toxicity withdrawal was very low (1.5%), but the incidence of CNS toxicity and CNS-related withdrawals were significantly higher in patients with prior oral INSTI-related CNS adverse events.
- Switching from integrase strand transfer inhibitors (INSTIs) based triple therapy to dual therapy in people with HIV?1 infection (PWH): the French hospital database on HIV (ANRS CO4 FHDH) real?life experience () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_202;
Materials and PWH who initiated a first INSTI-based 3-DR containing bictegravir, dolutegravir, elvitegravir or raltegravir between 2008 and 2018 for at least 1 year and had a controlled viral load (HIV-RNA <50 cp/ml) before switching to an INSTI-2-DR were included. Using IPW models on real-world data, no difference was observed in virological and clinical outcomes between PWH on INSTI 3-DR switching to INSTI 2-DR or remaining on 3-DR.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Causes of discontinuation of long?acting cabotegravir and rilpivirine in clinical practice: results from the prospective multicentre SCOLTA cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_197;
The frequency of LA CAB+RPV interruptions for AE was higher in this real-life cohort than in registrational trials, while high virological efficacy was seen, with 1% virological failure. To continue the active surveillance of AE in cohort studies will be critical to understanding the key to LA persistence.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Antiretroviral treatment in PLWH with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: a real?world cohort analysis () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_188;
To continue the active surveillance of AE in cohort studies will be critical to understanding the key to LA persistence. There are currently no data from European studies solely focusing on virological outcomes in treatment na
- Sunlenca (lenacapavir) / Gilead, bictegravir (GS-9883) / Gilead
Metabolic changes at 48 weeks in virologically suppressed people with HIV switching from complex antiretroviral regimens to bictegravir plus lenacapavir: ARTISTRY?1 trial () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_180;
P2/3
After 48 weeks of follow-up, metabolic parameters generally improved after switching from baseline complex antiretroviral regimens to BIC+LEN. Phase III studies are underway to confirm the efficacy and safety of BIC+LEN combination therapy in PWH.
- Sunlenca (lenacapavir) / Gilead, bictegravir (GS-9883) / Gilead
Pharmacokinetic (PK) analysis of oral once?daily bictegravir (BIC) plus lenacapavir (LEN) administered separately (BIC 75 mg + LEN 25 mg; BIC 75 mg + LEN 50 mg) and as BIC/LEN 75/50 mg single?tablet regimen to support phase III dose selection () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_179;
P2/3
Our analyses support the use of BIC/LEN 75/50 mg FDC for phase III, which will match the exposure experience of BIC 75 mg + LEN 50 mg in phase II. This dose combination was chosen based on efficacy, safety, cumulative PK in phase II and rBA, and additional consideration of the exposure coverage for potential missed doses, projected by popPK analysis.
- bictegravir (GS-9883) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
HIV pre?exposure prophylaxis (PrEP) failures in a large observational cohort from Poland with expansion of A6 subtype transmissions () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_150;
This dose combination was chosen based on efficacy, safety, cumulative PK in phase II and rBA, and additional consideration of the exposure coverage for potential missed doses, projected by popPK analysis. Users were started on tenofovir alafenamide/emtricitabine/bictegravir in the median of 10.5 (IQR 7
- Antiretroviral therapy in pregnancy in England in 2019?2022: common regimens and treatment modifications () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_130;
Among pregnancies conceived on ART, most common (reported in >5%) first regimens were efavirenz (EFV) + tenofovir disoproxil fumarate (TDF) + emtricitabine (FTC) (13.5% [267/1974]), rilpivirine (RPV) +TDF+FTC (11.6% [228/1974]), darunavir/ritonavir (DRV/r) +TDF+FTC (8.0% [158/1974]), dolutegravir (DTG) + lamivudine (3TC) + abacavir (ABC) (7.7% [152/1974]), and raltegravir (RAL) +TDF+FTC (6.4% [127/1974]). Where ART was initiated during pregnancy (55.7% [234/420] diagnosed antenatally), median gestational age at start was 15 weeks (IQR 12
- || bictegravir (GS-9883) / Gilead, Isentress (raltegravir) / Merck (MSD)
PK/PD data, Journal: Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure. (Pubmed Central) - Oct 23, 2024
Pharmacokinetic investigations on hepatically cleared drugs should not be conducted before the fifth week after delivery to fully characterize the effect of pregnancy on drug exposure. Because physiological changes remain after delivery, early measurements can underestimate the pregnancy effect on pharmacokinetics, leading to suboptimal dosing recommendations during pregnancy.
- | bictegravir (GS-9883) / Gilead
Journal: Birth outcomes following bictegravir exposure during pregnancy. (Pubmed Central) - Oct 16, 2024
These findings provide preliminary data without significant safety concerns for fetal bictegravir exposure in this United States cohort. Comparative data and continued surveillance of outcomes among infants exposed to bictegravir during gestation are warranted.
- | bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Journal: Antiretrovirals and Weight Change: Weighing the Evidence. (Pubmed Central) - Oct 15, 2024
We review weight changes in major randomized trials of pre-exposure prophylaxis (PrEP) and initial and switch HIV therapy, highlighting the challenges to assessing the role of ART in weight change. This examination forms the basis for a model that questions assumptions regarding an association between INSTI and TAF and excessive weight gain and calls for more careful consideration of these data when making HIV treatment decisions.
- Clinical features and resistance patterns during second-generation INSTI failure: the ROSETTA registry () - Oct 15, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_68;
The selection of INSTI resistance was already seen at relatively low VL. Notably, resistance mutations G118R and R263K were not observed in cases with previous 1st-gen INSTI exposure, suggesting different resistance pathways based on past exposure.
- | bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
New trial: MICTLAN: Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN (clinicaltrials.gov) - Oct 7, 2024
P=N/A, N=378, Completed, Sponsor: Instituto Mexicano del Seguro Social
- || Vemlidy (tenofovir alafenamide) / Gilead
Clinical, Retrospective data, Review, Journal: Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis. (Pubmed Central) - Sep 21, 2024
Notably, resistance mutations G118R and R263K were not observed in cases with previous 1st-gen INSTI exposure, suggesting different resistance pathways based on past exposure. Tenofovir alafenamide use in people living with HIV is associated with significant alterations in lipid profile.
- |||| Sunlenca (lenacapavir) / Gilead, bictegravir (GS-9883) / Gilead
Enrollment open: Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 (clinicaltrials.gov) - Sep 20, 2024
P2/3, N=75, Recruiting, Sponsor: Gilead Sciences
Tenofovir alafenamide use in people living with HIV is associated with significant alterations in lipid profile. Not yet recruiting --> Recruiting
- | Preclinical, Journal: Comprehensive Database of HIV Mutations Selected During Antiretroviral In Vitro Passage Experiments. (Pubmed Central) - Sep 17, 2024
Mutations emerging from these experiments generally predict those observed in persons receiving the same ARV. However, there are notable differences in mutation frequencies between in vitro and in vivo settings.
- Drug-agnostic transcutaneously-refillable subdermal implant for ultra-long-acting delivery of antiretrovirals for HIV prevention (Limatambo 3/Channel 1) - Sep 10, 2024 - Abstract #HIVR4P2024HIVR4P_931;
Implant drug-agnosticity imparts flexibility for single- or multi-ARV delivery for PrEP or treatment, as well as combination with contraceptives, serving as a multiprevention technology. Importantly, cost of good analysis estimates drug-loaded implant could be as low as USD 36/year, substantiating clinical viability for adoption in low resource countries.
- | bictegravir (GS-9883) / Gilead
Journal: Mucocutaneous relapse during late latent syphilis as initial presentation of HIV infection. (Pubmed Central) - Sep 10, 2024
Opportunistic infections were excluded, and antiretroviral therapy with a bictegravir-based regimen was started. Syphilis was treated successfully with three doses of 2.4 million units of benzathine penicillin.
- Vemlidy (tenofovir alafenamide) / Gilead
Racial/Ethnic Disparities of Renal Outcomes in People with HIV (PWH) on Tenofovir Alafenamide (TAF) Based Antiretroviral Treatment (ART) Regimens in the Real World (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2355;
- Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-containing Antiretroviral Therapy (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2244;
- bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Impact of Switching to Bictegravir- or Dolutegravir-based Antiretroviral Therapy on Weight in People Living with HIV during the COVID-19 Pandemic (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2233;
- || bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Clinical, Journal, HEOR: Comparative Effectiveness of Switching to Bictegravir From Dolutegravir-, Efavirenz-, or Raltegravir-Based Antiretroviral Therapy Among Individuals With HIV Who are Virologically Suppressed. (Pubmed Central) - Aug 26, 2024
Similar results were observed at 12 months and in other sensitivity analyses. Our findings suggest that switching to bictegravir could be more effective in maintaining viral suppression than continuing with dolutegravir, efavirenz, or raltegravir.
- bictegravir (GS-9883) / Gilead
Incident cases of HIV infection in a de-medicalized pre-exposure prophylaxis program in Mexico City (Poster Exhibition) - Aug 9, 2024 - Abstract #HIVR4P2024HIVR4P_840;
PrEP efficacy was 99.95% in people with good adherence. No cases of resistance to tenofovir/emtricitabine were observed in incident infections with prior PrEP intake.
- Vocabria (cabotegravir oral) / ViiV Healthcare, bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Simple and rapid detection of HIV integrase inhibitors bictegravir, cabotegravir and dolutegravir in blood across clinical benchmark concentrations by lateral flow assay (Poster Exhibition) - Aug 9, 2024 - Abstract #HIVR4P2024HIVR4P_706;
The visual results permit assessments of INSTI pharmacokinetics that may inform optimal long-acting dosing intervals for individuals, indicate treatment adherence, and provide confidence that protective levels are present. The ability to use unprocessed whole blood supports simple testing of INSTI concentrations by laboratories, POC clinics, and self-testers.
- Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
Successful management of psoriasis in a patient with HIV using risankizumab (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4939;
At the time of presentation, he was receiving a combination of emcitrabine, tenofovir and bictegravir. Although there is limited data on the use of biologics in HIV patients, this case suggests that IL-23 inhibitors may be a valuable therapeutic option for this patient group.
- | Journal: First-trimester exposure to newer antiretroviral agents and congenital anomalies in a U.S. cohort. (Pubmed Central) - Aug 1, 2024
The odds of congenital anomalies among infants with first-trimester exposure to newer ARVs did not differ substantially from those unexposed to these specific ARVs, which is reassuring. Continued evaluation of these ARVs with larger studies will be needed to confirm these findings.
- |||||||| Sunlenca (lenacapavir) / Gilead, bictegravir (GS-9883) / Gilead
New P2/3 trial: Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 (clinicaltrials.gov) - Aug 1, 2024
P2/3, N=75, Not yet recruiting, Sponsor: Gilead Sciences
- ||| Prezista (darunavir) / J&J, Pifeltro (doravirine) / Merck (MSD), Prezcobix (darunavir/cobicistat) / Gilead, J&J
Journal, Adverse events: Reversibility of Neuropsychiatric Adverse Events after Switching to Darunavir/Cobicistat or Doravirine in Men on INSTI-Based Regimen. (Pubmed Central) - Jul 31, 2024
0.05. NPAEs seem to improve after switching to a DRV/c- or DOR-based regimen after the first 4 and 12 weeks.
- | Tivicay (dolutegravir) / ViiV Healthcare
Preclinical, Journal: Antiretroviral drug dolutegravir induces inflammation at the mouse brain barriers. (Pubmed Central) - Jul 10, 2024
NPAEs seem to improve after switching to a DRV/c- or DOR-based regimen after the first 4 and 12 weeks. To address this question, we evaluated the effect of two INSTIs, DTG and bictegravir (BTG), on folate transporters and receptor expression at the mouse BCSFB and the BBB in
- | bictegravir (GS-9883) / Gilead
Journal: Development and Validation of a High-Performance Liquid Chromatography Coupled With Ultraviolet Detection Method for Quantification of Bictegravir in Human Plasma. (Pubmed Central) - Jun 25, 2024
This study successfully established a high-performance liquid chromatography coupled with ultraviolet detection method for determining plasma BIC concentrations. This method is simple, selective, sensitive, and accurate, making it suitable for clinical monitoring and pharmacokinetic studies of BIC.
- | bictegravir (GS-9883) / Gilead, Vemlidy (tenofovir alafenamide) / Gilead
Journal: Systemic delivery of bictegravir and tenofovir alafenamide using dissolving microneedles for HIV preexposure prophylaxis. (Pubmed Central) - Jun 9, 2024
For TAF MNs, a rapid release of drug and metabolism of TAF into TFV were obtained from the plasma samples. This work has shown that the proposed transdermal drug delivery platform could be potentially used as an alternative method to systemically deliver ARV drugs for HIV PrEP.
- | bictegravir (GS-9883) / Gilead
Journal: Management of enzyme de-induction in a woman with HIV on methadone maintenance switched from nevirapine- to bictegravir-based antiretroviral regimen. (Pubmed Central) - Jun 6, 2024
This work has shown that the proposed transdermal drug delivery platform could be potentially used as an alternative method to systemically deliver ARV drugs for HIV PrEP. No abstract available